More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Imiquimod [99011-02-6]
Chemical Structure
Chemical Structure
Chemical Structure

Imiquimod [99011-02-6]

Research Use Only
AG-CR1-3569
AdipoGen Life Sciences
CAS Number99011-02-6
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight240.3
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Imiquimod
  • Delivery Days Customer
    10
  • ADR Class
    6.1
  • CAS Number
    99011-02-6
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Excepted quantity
  • Molecular Formula
    C14H16N4
  • Molecular Weight
    240.3
  • Scientific Description
    Chemical. CAS: 99011-02-6. Formula: C14H16N4. MW: 240.3. Immune response modulator. Anti-inflammatory. TLR7 agonist. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB. Caspase-3 activator that directly induces procaspase-3 cleavage. Anti-cancer compound. Apoptosis inducer. Antiproliferative, independent of immune system activation or function. Antiviral and anti-angiogenic. Approved treatment for external genital warts caused by human papillomavirus infection. - Immune response modulator [1, 2]. Anti-inflammatory [3, 5]. TLR7 agonist [3, 5]. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB [3, 5]. Caspase-3 activator that directly induces procaspase-3 cleavage [4]. Anti-cancer compound [4, 9]. Apoptosis inducer [4, 9]. Antiproliferative, independent of immune system activation or function. Antiviral [10] and anti-angiogenic [6, 7, 8]. Approved treatment for external genital warts caused by human papillomavirus infection [10].
  • SMILES
    CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
  • Storage Instruction
    -20°C,2°C to 8°C
  • UN Number
    UN 2811
  • UNSPSC
    12352200

References

  • Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999)
  • A review of the applications of imiquimod: a novel immune response modifier: T.A. Syed, et al.; Exp. Opin. Pharmacother. 2, 877 (2001)
  • Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
  • Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod: M. Schon, et al.; J. Natl. Cancer Inst. 95, 1138 (2003)
  • Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003)
  • In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004)
  • Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005)
  • Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005)
  • The antitumoral mode of action of imiquimod and other imidazoquinolines: M. Schon & M.P. Schon; Curr. Med. Chem. 14, 681 (2007)
  • The pharmacology of endosomal TLR agonists in viral disease: D.R. Averett, et al.; Biochem. Soc. Trans. 35, 1468 (2007)